Posting Date: March 3, 2021

Closing Date: March 13, 2027 11:30 a.m. ET

Reference Number: 21-022256

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – Service Agreement

At the National Cancer Institute (NCI), The Laboratory of Pathology (LP) is an integral component of the research and clinical community. Our goal is to be a globally recognized center of excellence in disease research, clinical diagnostics, and pathology education. The mission of the Laboratory of Pathology is to achieve the highest level of quality in research, diagnostics, and education. We support the research mission of the NCI by investigating the biology and genetics of cancer and other diseases, developing and applying leading edge technology to diagnostic pathology, providing collaborative support for clinical research protocols In this endeavor, we value scientific originality, integrity, and productivity while maintaining the highest level of ethical principles..

The National Cancer Institute plans to purchase three (3) Service Agreements for (S/N: 278881582) ViiA 7; (S/N: 278881408) ViiA 7; (S/N: 272002948) StepOnePlus Real-Time PCR System from Life Technologies. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on March 13, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

Laboratory of Pathology performs molecular testing to assist in the diagnosis of a variety of cancers. The laboratory develops tests that assist in pathologic diagnosis, predict prognosis and identify potential targets for rational personalized therapies. ViiA7 is used for these studies. Yearly maintenance is required for equipment calibration to maintain the highest standard performance for complex scientific experimentation and batch-to batch data comparison. This requires the instrument to be maintained and serviced by the original manufacturer. Original manufacturer service is also required to avoid nullifying the warranty.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request